Harmony Biosciences has entered into an exclusive licensing agreement with Bioprojet for the development, manufacturing & commercialization of TPM-1116 across the US & Latin American territories as a treatment for narcolepsy & other sleep/wake disorders
Under the collaboration, Bioprojet will receive a $25.5M upfront license fee for exclusively developing, manufacturing & commercializing TPM-1116, ~$127.5M development & regulatory milestones, ~$240M sales-based milestones plus mid-teens sales-based royalties
TPM-1116 is a potent & selective oral orexin-2 receptor (OX2R) agonist that demonstrated a robust safety profile and a potential for QD dosing in its preclinical study
Ref: Harmony Biosciences | Image: Harmony Biosciences
Related News:- Harmony Biosciences to Acquire Zynerba for ~$200M
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
